Ionis grants Recordati rights to zilganersen for Alexander disease

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US. Recordati will handle regulatory filings and commercial operations ex-US, including supporting early access initiatives. Ionis will receive a $30m upfront payment as part of the deal. Credit: Piotr Swat / Shutterstock.com. Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US. Ionis will retain the responsibility for commercialising the RNA-targeted medicine within the US and will remain the global…

Salong Debbarma · 2026-06-26

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.

Source: Pharmaceutical Technology